RedHill Biopharma (RDHL) director Tsimchi Ofer details initial share and option holdings
Rhea-AI Filing Summary
RedHill Biopharma Ltd. director Tsimchi Ofer filed an initial Form 3 reporting his equity holdings in the company. The filing shows direct ownership of 146,250,000 Ordinary Shares and 3,644 American Depositary Shares (ADSs), which are convertible into Ordinary Shares at the holder’s election with no expiration date.
Ofer also reports 14,625 unvested restricted share units, each linked to one ADS and settled in Ordinary Shares. In addition, he holds stock options over 150,000, 90,000 and 180,000 Ordinary Shares, with exercise prices of $5,000, $4,870 and $7,080 per ADS, expiring on May 6, 2029, March 25, 2030 and April 28, 2031, respectively.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Tsimchi Ofer
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 36,440,000 shares (Direct);
Stock Option (Right to Buy) — 420,000 shares (Direct);
Ordinary Shares — 146,250,000 shares (Direct)
Footnotes (5)
- F1. Represents 14,625 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.
- F2. Represents 3,644 ADSs, which are convertible at any time, at the holder's election and have no expiration date.
- F3. Represents stock option to purchase 150,000 Ordinary Shares (equivalent to 15 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.
- F4. Represents stock option to purchase 90,000 Ordinary Shares (equivalent to 9 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030.
- F5. Represents stock option to purchase 180,000 Ordinary Shares (equivalent to 18 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Tsimchi Ofer’s Form 3 for RedHill Biopharma (RDHL) show?
The Form 3 discloses Tsimchi Ofer’s initial ownership in RedHill Biopharma. It lists his direct Ordinary Share holdings, ADSs, unvested restricted share units, and several stock option grants, providing a baseline view of his equity position as a director with no new buy or sell activity.
What stock options in RedHill Biopharma (RDHL) does Tsimchi Ofer hold?
Ofer holds three stock option grants over 150,000, 90,000 and 180,000 Ordinary Shares. These options are fully vested and exercisable, with exercise prices of $5,000, $4,870 and $7,080 per ADS, expiring between 2029 and 2031 under the RedHill 2010 Option Plan.
Are there any buy or sell transactions reported in this RDHL Form 3?
No buy or sell transactions are reported in this Form 3. The entries are classified as holdings, meaning the document serves as an initial statement of beneficial ownership, not a record of recent market purchases, sales, or option exercises by Tsimchi Ofer.
When do Tsimchi Ofer’s RDHL stock options expire and at what exercise prices?
The options expire in 2029, 2030 and 2031 with different exercise prices. Specifically, the grants have exercise prices of $5,000, $4,870 and $7,080 per ADS, providing long-dated potential for additional Ordinary Share ownership.